Ignite Creation Date:
2024-05-06 @ 9:39 AM
Last Modification Date:
2024-10-26 @ 12:17 PM
Study NCT ID:
NCT03036488
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-12
First Post:
2017-01-27
Brief Title:
Study of Pembrolizumab MK-3475 Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer TNBC MK-3475-522KEYNOTE-522
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-07
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-27
First Submit QC Date:
January 27 2017
Study First Post Date:
2017-01-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-11
Last Update Post Date:
2024-07-12
Last Update Post Date Type:
ACTUAL